Skip to content

Pfizer, Flynn Fined £70 Million for Epilepsy Drug Prices

  • Pfizer, Flynn Pharma fined by UK’s CMA for unfair prices
  • Companies de-branded Epanutin to inflate prices of the drug
Pfizer Inc.'s European Facilities With Drug Maker Soaring On Vaccine
Photographer: Nathan Laine/Bloomberg
Updated on

Pfizer Inc. and Flynn Pharma Ltd. were fined a combined £70 million ($83.6 million) after UK antitrust authorities said the firms charged “unfairly high prices” for a drug used to control epileptic seizures.

Pfizer was fined £63 million and Flynn Pharma, £6.7 million, the Competition and Markets Authority said Thursday. The companies exploited a loophole by de-branding the drug known as Epanutin, so that its price wasn’t regulated the same way as other branded drugs. Over a four-year period, Pfizer charged prices between 780% and 1,600% higher than it sold for previously.